Cardiovascular safety of therapies for type 2 diabetes.

about

The regulatory role of DPP4 in atherosclerotic disease.

P2860

Q33805518-CEBB95FC-BD42-4898-AD02-2F7B2A932E1D

P2860

Cardiovascular safety of therapies for type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38960547

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cardiovascular safety of therapies for type 2 diabetes.

@en

type

Item

label

Cardiovascular safety of therapies for type 2 diabetes.

@en

prefLabel

Cardiovascular safety of therapies for type 2 diabetes.

@en

P1476

Cardiovascular safety of therapies for type 2 diabetes.

@en

P2093

Puneet Gupta

http://www.w3.org/2001/XMLSchema#string

William B White

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

P304

13-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1239707

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27652617

http://www.w3.org/2001/XMLSchema#string

P932

5523835

http://www.w3.org/2001/XMLSchema#string

Cardiovascular safety of therapies for type 2 diabetes.

about

P2860

P2860

Cardiovascular safety of therapies for type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932